Genetic architecture of Tourette syndrome: our current understanding

Laura Domènech[1,2,]*, Carolina Cappi[3,4,5,]* and Matt Halvorsen[6,]* [ID]

[1]Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; [2]Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Boston, MA, USA; [3]Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA; [4]The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; [5]Department of Psychiatry, School of Medicine, University of São Paulo, São Paulo, Brazil and [6]Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Abstract

Tourette syndrome (TS) is a severe neuropsychiatric disorder characterized by recurrent, involuntary physical and verbal tics. With a prevalence as high as 1% in children, a deeper understanding of the etiology of the disorder and contributions to risk is critical. Here, we cover the current body of knowledge in scientific literature regarding the genetics of TS. We first review the history and diagnostic criteria for TS cases. We then cover the prevalence, and begin to address the etiology of the disorder. We highlight long-standing evidence for a genetic contribution to TS risk from epidemiology studies focused on twins, families, and population-scale data. Finally, we summarize current large-scale genetic studies of TS along specific classes of genetic variation, including common variation, rare copy number variation, and *de novo* variation that impact protein-coding sequence. Although these variants do not account for the entirety of TS genetic risk, current evidence is clear that each class of variation is a factor in the overall risk architecture across TS cases.

Introduction

Definition of illness

Tourette syndrome (TS) is a childhood-onset chronic complex neuropsychiatric disorder characterized by multiple motor tics and at least one vocal tic persisting for more than 1 year (American Psychiatric Association, 2013; Robertson et al., 2017). Tics are defined by sudden, rapid, recurrent, nonrhythmic motor movements or vocalizations. They are generally involuntary and can include almost any muscle group or vocalization, although certain tics are common across TS patients, such as facial grimacing and eye blinking (American Psychiatric Association, 2013). Tics can be simple, involving only one group of muscles or sounds over a short duration, or complex, featuring coordinated patterns of movements, sounds, or speech that are longer in duration (American Psychiatric Association, 2013; Robertson et al., 2017). Tics wax and wane in severity, intensity and frequency, and they can persist, disappear and change in typology and topography over time (American Psychiatric Association, 2013; Robertson et al., 2017). Most individuals are able to suppress their tics, although only for a limited period of time and at the expense of unpleasantness (Leckman, Walker, & Cohen, 1993). Although some studies have reported abnormalities in the cortico–striato–thalamo–cortical (CSTC) circuit of TS patients (Crittenden & Graybiel, 2011; Singer, 2013), the biology and molecular pathogenesis underlying this disorder remains unknown. Current treatments only provide partial relief of symptoms and often produce side effects (Robertson, 2000).

History

TS is named after Georges Albert Édouard Brutus Gilles de la Tourette, who in 1885 published the first clear description of this condition present in nine patients (Kushner, 2000; McNaught & Mink, 2011; Tourette, 1885). Although Gilles de la Tourette was the first person to formally describe symptoms, course of illness and predisposing cause of TS, earlier descriptions of tics exist. A document dated back to 1498 exists describing a priest who presented physical and vocal tics (McNaught & Mink, 2011). Patients with involuntary movements and vocalizations were reported in 1663 by William Drage (who reported the possible first case in UK, Mary Hall); 1825, by Jean Marc Gaspard Itard; 1873, by Armand Trousseau; and 1884, by Hughlings Jackson (McNaught & Mink, 2011; Robertson et al., 2017; 125 Years of Tourette Syndrome: The Discovery, Early History & Future of the Disorder, n.d.). By 1921, physicians such as Sandor Ferenczi began addressing TS from a psychoanalytical perspective (Ferenczi, 1921; Kushner, 2000; McNaught & Mink, 2011). It was not until the 1960–1970s that the

psychoanalytical interpretation was questioned, when Arthur Shapiro began to treat TS patients with the neuroleptic drug haloperidol (McNaught & Mink, 2011; Shapiro & Shapiro, 1968). When Shapiro and colleagues concluded that the etiology of Tourette symptoms was organic, and not a consequence of 'bad parenting', many more families began to connect by the early 1970s, establishing the US Tourette Syndrome Association (TSA) in 1972 (Kushner, 2000; Robertson et al., 2017). In 1980, TS was included in the third edition of the American Diagnostic and Statistical Manual of Mental Disorders (DSM-III), although tics had been included in the first edition of DSM, in 1952 (American Psychiatric Association, 1952; Robertson et al., 2017).

Diagnostic classification and criteria

In the DSM-5, TS belongs to a spectrum of neurodevelopmental conditions referred to as Tic Disorders, along with the persistent (chronic) motor or vocal tic disorder (which requires the presence of either motor or vocal tics), the provisional tic disorder (characterized by the presence of tics for less than a year), and the other specified and unspecified tic disorders (American Psychiatric Association, 2013).

The specific diagnostic criteria for TS in the latest edition of the DSM (DSM-5) are: (a) both multiple motor and one or more vocal tics have been present at some time during the illness, although not necessarily concurrently; (b) the tics may wax and wane in frequency but have persisted for more than 1 year since first tic onset; (c) onset is before age 18 years; and (d) the disturbance is not attributable to the physiological effects of a substance or another medical condition.

Different assessment tools have been developed in order to measure tic repertoire and severity in an individual. Currently, the most commonly used is the Yale Global Tic Severity Scale, which provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic symptoms (Leckman et al., 1989).

Epidemiology (lifetime prevalence estimates, risk factors, morbidity, mortality, and comorbidities)

Prevalence, morbidity, comorbidities, and mortality

TS has a worldwide estimated prevalence of 0.3–1% in children and can lead to a substantial decrease in quality of life, especially when tics are severe or when other comorbidities are present (American Psychiatric Association, 2013; Knight et al., 2012; Robertson, 2008; Scharf et al., 2015). Notably, there is a well-established gender imbalance in the prevalence of TS, with a male-to-female ratio of 2–4:1 (American Psychiatric Association, 2013; Freeman et al., 2000; Knight et al., 2012). Tics present at an average age at onset of 4–6 years, typically reach the peak severity between 10 and 12 years, and decrease in severity during adolescence for 50–75% of patients (American Psychiatric Association, 2013; Leckman et al., 1998). Groth et al. published a large prospective clinical study where they indicate that, in adulthood, most cases (59.5%) have a mild form of the disorder, with remission reported in 17.7% of diagnoses (Groth, Mol Debes, Rask, Lange, & Skov, 2017). A small group (22.8%) presented moderate or severe and debilitating tic symptoms (Groth et al., 2017). Adult TS is notable for being associated with a lifelong disability in 15% of cases (Elstner, Selai, Trimble, & Robertson, 2001; Leckman, Bloch, Scahill, & King, 2006).

More than 85% of individuals with TS present a lifetime diagnosis of any neuropsychiatric disorders (Hirschtritt et al., 2015). Among the most common comorbid disorders are obsessive-compulsive disorder (OCD, 50%) and attention deficit hyperactivity disorder (ADHD, 54%) (Hirschtritt et al., 2015). Other conditions have also been described in patients with TS including major depression, non-OCD anxiety, conduct disorder, learning disorder, as well as mood and disruptive behavior (Hirschtritt et al., 2015).

In some instances, TS includes physical, orthopedic or neurological self-injury related to forceful movements (American Psychiatric Association, 2013; Stafford & Cavanna, 2020), and when compared to controls, TS/chronic tic disorder (CTD) patients have been shown to have higher risk for attempting suicide or dying by suicide (Fernández de la Cruz et al., 2017). In a nationwide prospective study comprising children born between 1960 and 2012 in Denmark, the all-cause mortality rate ratio (including suicide causes) has been reported to be 1.63 in TS patients compared to controls, and 1.39 after adjusting for comorbidities (Meier, Dalsgaard, Mortensen, Leckman, & Plessen, 2017).

Etiology

Analyses of TS heritability suggest a complex etiology that includes multiple risk factors. The most well-evidenced set of risk factors are those that are genetic. Much of the progress in our study of the genetic risk factors has only been made in the last few decades (Fig. 1).

Apart from TS risk factors, there are additional factors that can increase tic severity. According to the DSM-5, they can be divided into three different groups: (a) temperamental (anxiety, stress, excitement, and exhaustion); (b) environmental (e.g. observing gestures or sounds in other persons may result in echopraxia or echolalia, high temperatures); and (c) genetic and physiological (genetic variation, obstetrical complications, older paternal age, lower birth weight, and maternal smoking during pregnancy) (American Psychiatric Association, 2013; Robertson et al., 2017).

Genetic epidemiology

Twin studies

Twin studies focused on TS and the more generalized presence of tics have offered longstanding support for a genetic contribution to risk. An early study reported diagnostic concordance values for mono- and di-zygotic twins (rMZ and rDZ, respectively) of 0.77 and 0.23 for the presence of any tics in general, and a lower rMZ and rDZ of 0.53 and 0.08 for formal TS diagnosis (Price, Kidd, Cohen, Pauls, & Leckman, 1985). In spite of this study only featuring 43 twin pairs and thus being underpowered, it suggested that tic severity itself is a complex trait with genetic and non-genetic contributions, and that it is more likely for monozygotic twins to both have the presence of tics than it for them to both be diagnosed with full-blown TS. An expansive twin study utilizing the Swedish medical registry (*n* = 10 895 twin pairs) noted rMZ and rDZ values in line with initial estimates, and an rMZ substantially higher than rDZ (Lichtenstein, Carlström, Råstam, Gillberg, & Anckarsäter, 2010). It also reported a twin-based heritability estimate (i.e. concordance of presence/absence of the trait across twin pairs) of 0.56 for the presence of tics (Lichtenstein et al., 2010). Most recently, large-scale meta-analyses of summary

Fig. 1. Key genetic studies and findings in TS. Adapted from Robertson et al. (2017). Twin studies in yellow; non-twin studies in green; linkage studies in salmon; genome-wide association studies (GWAS) in blue; rare copy number variant (CNVs) in white; whole-exome sequencing (WES) in gray. TS, Tourette syndrome; OCD, obsessive-compulsive disorder; ADHD, attention deficit hyperactivity disorder; CTD, chronic tic disorder; rMZ, monozygotic twin correlation (for diagnosis); rDZ, dizygotic twin correlation (for diagnosis); SNP, single-nucleotide polymorphism; LD, linkage disequilibrium; eQTL, expression quantitative trait locus; mQTL, methylation quantitative trait locus; h2-snp, SNP-based heritability estimate; RR, relative risk; HDC, histidine decarboxylase; NRXN1, neurexin 1.

statistics reported for 17 804 traits across 2748 publications led to an rMZ for Tic Disorders of 0.63 across 2658 pairs, and an rDZ of 0.34 across 3780 pairs, in line with initial estimates (Polderman et al., 2015). These concordance rates are lower than other more well-studied neuropsychiatric disorders such as schizophrenia and bipolar disorder (rMZ of 0.76 and 0.82 across 19 841 and 9251 pairs respectively) (Polderman et al., 2015), suggesting a greater comparative role for the influence of non-genetic factors on TS risk.

Non-twin family studies

Population-scale epidemiological studies of non-twin families also support genetic contribution to tics (Browne et al., 2015; Mataix-Cols et al., 2015). Research of thorough, population-wide registry data from Scandinavia has proven the most appealing subject of these studies. One key example is a study focused on the Swedish registry to identify 4826 individuals with TS or CTD, and matched them at a 1:10 ratio with unaffected, unrelated

individuals from the registry (Mataix-Cols et al., 2015). Researchers then compared the likelihood of affected individuals having a first-degree relative with TS or CTD relative to matched unaffected individuals. Consistent with rDZ twin concordance estimates, first-degree relatives of TS/CTD cases were far more likely to have TS/CTD themselves [odds ratio (OR) 18.69, 95% confidence interval (CI) 14.53–24.05], as were second-degree relatives (OR 4.58, 95% CI 3.22–6.52) and third-degree relatives (OR 3.07, 95% CI 2.08–4.51). Such substantial increases in relative risk are consistent with a subset of risk factors that are genetic in origin. This study estimated the total heritability due to shared genetic factors at 0.77, with the remainder being attributed to non-shared environmental effects. Although earlier twin studies reported a higher amount of genetic heritability between male twins (Qi, Zheng, Li, & Xiong, 2017), this study failed to find additional evidence in support of this, instead suggesting tic heritability levels in males and females are similar. At around the same time, a similar study was published focused specifically on Danish registry data (Browne et al., 2015). Out of around 1.7 million included Danish individuals born from 1980 to 2007, it identified 5596 individuals total with a diagnosis of TS or CTD that were suitable for analysis. It reported a substantially elevated recurrence risk for siblings of TS/CTD cases (18.63%, 95% CI 15.34–22.63) (Browne et al., 2015), in line with the elevated risk observed in first-degree relatives of cases in the Swedish study. Both studies offer strong lines of evidence that within large populations, TS/CTD cluster within families (Browne et al., 2015; Mataix-Cols et al., 2015). The most plausible explanation for this clustering is a genetic contribution to TS/CTD risk.

Genetics

Linkage studies

Linkage-based approaches have thus far not yielded a substantial number of findings in published research in TS. Initial studies focused on large, multi-generational pedigrees operated on the theory that the presence of multiple TS-affected individuals within these pedigrees were due to the presence of one or a few highly penetrant genetic risk factors (Curtis, Robertson, & Gurling, 1992; Eapen, Pauls, & Robertson, 1993; Kurlan et al., 1986). Most studies simply describe the results of linkage study, where segments that are shared to a nominal degree of significance are described. Although linkage peaks have been observed in individual family structures, none replicate across families, and none (save for one, that has never been replicated) have met strict statistical criteria for being a genome-wide significant linkage peak (O'Rourke, Scharf, Yu, & Pauls, 2009). One example in line with the autosomal dominant model initially proposed with pedigrees such as these is (Ercan-Sencicek et al., 2010), where a two-generation non-consanguineous family is described consisting of an affected father, unaffected mother and eight children, all of which are affected. Linkage analysis indicated a shared region in a 3.4 cM region of chromosome 15, around the histidine decarboxylase (*HDC*) gene region. Subsequently, researchers found that the father was heterozygous for a stop-gain variant within this gene that had been transmitted to all eight affected children. Researchers failed to find additional *HDC* stop-gain variants in an additional 720 TS cases. Thus far, *de novo* coding *HDC* mutations in TS have not been observed in more recent studies (Wang et al., 2018). One follow-up hypothesis that is insufficiently explored in earlier pedigree study but now being explored

more fully in pedigree studies of psychiatric cohorts is that families with a large number of affecteds may carry a heavy load of common risk variation (de Jong et al., 2018; Szatkiewicz et al., 2019). It is also possible that, in some of these pedigrees, higher-penetrance rare noncoding risk variants are present in the data that have not been detected via current selection criteria that are biased heavily toward coding annotations. As our understanding of the noncoding genome accelerates, our ability to identify the subset of these variants that are more likely to make substantial contributions to risk will increase.

Genome-wide association studies of common variation with TS

The first TS genome-wide association study (GWAS) of common genetic variants (allele frequency ≥0.01) included 1285 cases and 4964 controls, and was underpowered for common risk variant detection (Scharf et al., 2013). No single genome-wide significant loci were detected in the study, but analysis of the summary statistics suggested that this was due to insufficient sample size. In assessing the top-ranked linkage disequilibrium (LD)-independent single nucleotide polymorphisms (SNPs) (412 with $p < 0.001$) nominally significant enrichments were noted for overlap with expression and methylation quantitative trait loci (eQTL and mQTL respectively) derived from brain tissue.

The largest and most recent TS GWAS included newly genotyped cases and controls (referred to as GWAS2) alongside samples from the prior described set of results (herein referred to as GWAS1) for a combined analysis consisting of 4819 TS cases and 9488 controls (Yu et al., 2019). It reports a trait heritability derived from common genetic variation (h^2-snp) across the full cohort of 0.21 with a standard error (S.E.) of 0.024. Authors note that the GWAS1 cohort h^2-snp (0.57, S.E. = 0.1, $p = 1 \times 10^{-9}$) is substantially higher than that of the newest 'GWAS2' batch of samples (0.29, S.E. = 0.04, $p = 6 \times 10^{-14}$). It is reasoned that this is due to cases within GWAS1 being enriched for the presence of at least one affected sibling (i.e. multiplex family history), which would be consistent with a particularly heavy load of common risk variation within these samples. Across the full meta-analysis, one genome-wide significant hit was detected, near the Fms Related Receptor Tyrosine Kinase 3 (*FLT3*) gene. The locus failed to replicate in an independent cohort of 1172 cases and 6068 controls, a standard in statistical genetics that is generally required to be met in order to formally implicate an individual variant with risk.

Authors of the most recent TS GWAS also found that the GWAS summary statistics could be used to calculate sample-level genetic risk Scores (GRS) that were predictive of TS case status and of tic severity (Yu et al., 2019). GRS calculation in human samples was adapted from agricultural genetic work, where it had been used to more effectively select crops and livestock for breeding that carry preferable traits. Although contemporary methods have grown more complex, GRS values are in general calculated for single samples by taking independent variation associated with a trait at some level of significance (say, $p < 0.05$) and defining the risk score as a weighted sum of the number of alleles for each variant multiplied by the relative risk or protection conferred by each allele copy. In doing this with the TS summary statistics, authors found that TS GRS values calculated across an independent population-based sample was predictive of TS case status (OR 1.33, $p = 5 \times 10^{-9}$) and of tic spectrum case status (OR 1.20, $p = 5 \times 10^{-4}$). In a manner consistent with heritability calculations in multiplex-dominated GWAS1 *v.*

GWAS2, authors also reported that multiplex TS cases carried higher GRS values than simplex TS cases ($p = 0.027$). Finally, they noted a significant positive correlation between case GRS values and recorded worst-ever tic severity ($\beta = 0.93$, S.E. $= 0.42$, $p = 0.03$). This correlation is consistent with the spectrum nature of tic severity and tic diagnoses, and suggests that individuals with more severe CTD and formal TS are more likely to carry high genetic burden for TS.

Critically, data from the most recent TS GWAS provides genetic insight into the comorbidities observed for the disorder. We computed genetic correlations between the TS dataset and publicly available GWAS datasets for other psychiatric disorders using LDSC v1.0.1 (Bulik-Sullivan et al., 2015). The correlation patterns were concordant with comorbidities observed in TS patients (Fig. 2). Specifically, a particularly high genetic correlation with OCD is observed ($r_g = 0.42$, S.E. $= 0.09$), along with a high genetic correlation with ADHD ($r_g = 0.21$, S.E. $= 0.05$). As described earlier, these disorders are the most commonly described TS comorbidities. Interestingly, although anorexia nervosa (AN) and OCD are highly comorbid with one another, and have been reported to have a high genetic correlation (Yilmaz et al., 2018), the genetic correlation between TS and AN is very low. This result is in line with TS comorbidity statistics, and suggests that genetic architecture shared between TS and OCD is distinct from the architecture shared between OCD and AN.

Rare copy-number variants

Rare copy-number variants (CNVs) have been shown to be significant risk factors for several neuropsychiatric disorders (Levy, Xu, Gogos, & Karayiorgou, 2012), including for TS (Levy et al., 2012; McGrath et al., 2014; Nag et al., 2013; Sundaram, Huq, Wilson, & Chugani, 2010). CNVs involve the deletion or duplication of large genomic regions (often over 100 000 base pairs) (1000 Genomes Project Consortium et al., 2015; Mills et al., 2011; Redon et al., 2006; Sudmant et al., 2015) and as such, particularly large CNVs that impact the function of multiple genes have been implicated with neuropsychiatric disorders (Guyatt et al., 2018; Levy et al., 2012; Martin et al., 2019). The first CNV-focused study of TS was performed on DNA microarray data from 111 patients and 73 controls and indicated the presence of rare exonic CNVs in TS that had been previously implicated in other neuropsychiatric disorders, such as neurexin 1 (*NRXN1*) and catenin, alpha3 (*CTNNA3*) (Sundaram et al., 2010). These results suggested an overlap between CNV risk architecture for TS and for the other more well-studied neuropsychiatric disorders. Four other studies also found an overlap of rare CNVs between TS and autism spectrum disorder (ASD) (Huang et al., 2017; Levy et al., 2012; McGrath et al., 2014; Nag et al., 2013). The study from Fernandez et al. included 460 TS cases and 1131 controls, and although they didn't find a significant increase in the number of rare CNVs in cases *v.* controls, they detected rare CNVs in TS overlapping genes previously identified in ASD (Fernandez et al., 2012). Moreover, they noted an enrichment of CNVs overlapping genes involved in in histaminergic and GABAergic pathways in TS cases. Another study performed in two Latin American populations, which included 179 TS cases and 234 controls, identified two cases with ~400 kb deletions overlapping *NRXN1* and four duplications in Collagen Type VIII Alpha 1 Chain (*COL8A1*) (Nag et al., 2013). They validated these results identifying additional patients with rearrangements in *NRXN1 and COL8A1*, which were not found in controls.

They also found that cases had a significant excess of large CNVs (>500 kb) compared to controls. In 2014, McGrath et al. performed a cross-disorder study of CNVs in TS and OCD, involving 1086 TS, 1613 OCD, and 1789 control samples (McGrath et al., 2014). Although they didn't find a global CNV burden in the cross-disorder study or in the separate secondary analyses, they found a 3.3-fold increased burden of large deletions previously associated with other neurodevelopmental disorders in patients with TS/OCD.

The latest study using SNP microarray data analyzed 2434 TS cases and 4093 controls for rare CNVs and identified an excess of rare, large CNVs in TS cases compared to controls (OR 2.28, 95% CI 1.39–3.79, $p = 1.2 \times 10^{-3}$) (Huang et al., 2017). Moreover, they also identified two types of CNVs associated with TS risk at genome-wide significance: *NRXN1* deletions (OR 20.3, 95% CI 2.6–156.2) and *CNTN6* duplications (OR 10.1, 95% CI 2.3–45.4). More recently, Wang et al. analyzed 802 TS parent-proband trios from whole-exome sequencing (WES) and showed a statistically significant excess of rare *de novo* CNVs in TS relative to unaffected control trios (rate ratio = 2.2; $p = 2.5 \times 10^{-3}$) (Wang et al., 2018). In addition, they replicated this enrichment in complementary microarray data from 412 TS trios (rate ratio = 2.8; $p = 0.024$) and found *de novo* CNVs in TS cases that have been previously implicated with ASD (Sanders et al., 2015). These results in full suggest that the study of CNVs in larger cohorts may identify additional rare CNVs conferring risk for TS.

WES and its initial application to pedigrees

High throughput sequencing has allowed for the expansion of the focus of rare variant studies beyond CNVs to include insertion–deletions (indels) and single-nucleotide variants (SNVs). An effective implementation of this technology has been WES, where the ~1% of the human genome that codes for protein is specifically targeted for sequencing and variant discovery. Within psychiatric genetics this sequencing approach has been used to detect rare coding variants that are near-absent from the general population, some of which are inherited from parents while others are absent from both parents (i.e. *de novo* in origin). Genetic studies focused on these variants have identified single high-confidence risk genes and have helped to elucidate the biology underlying psychiatric disease.

WES was first applied to TS in a pedigree-focused context. The first study that applied WES to TS was focused on the role of rare coding variants inherited in multiplex families. WES was conducted on DNA from 10 members of a three-generation nonconsanguineous pedigree with seven individuals affected by TS/CTD, and found novel, nonsynonymous SNVs co-segregating with the chronic tic phenotype in three separate genes – Mitochondrial Ribosomal Protein L3 (*MRPL3*), DnaJ Heat Shock Protein Family (Hsp40) Member C13 (*DNAJC13*), and Orofacial Cleft 1 Candidate 1 (*OFCC1*) (Sundaram et al., 2011). In 2018, another group applied WES to DNA from six members of a three-generation nonconsanguineous TS multiplex family, and found a rare heterozygous nonsense mutation in PNKD Metallo-Beta-Lactamase Domain Containing (*PNKD*) that co-segregated with TS. The group characterized the functional consequences of the mutation in iPSC-derived neurons and demonstrated that the mutation was associated with the haploinsufficiency of some isoforms of the gene (Sun et al., 2018). The findings in these pedigrees were not subjected to a specific test of statistical significance, and the individual pedigree did not

Fig. 2. Genetic correlations between TS and other neuropsychiatric disorders from available GWAS summary statistics. Publicly available GWAS statistics for TS (4819 cases, 9488 controls) and for six separate neuropsychiatric disorders [ADHD (Demontis et al., 2019); AN (Duncan et al., 2017); ASD (Grove et al., 2019); BD (Stahl et al., 2019); OCD (International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD Collaborative Genetics Association Studies (OCGAS), 2018); SCZ (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014)] were obtained for genetic correlation calculations using LDSC v1.0.1 (Bulik-Sullivan et al., 2015). Sample sizes have been included for each disorder on the *X* axis. Significant genetic correlations are defined as those with a *p* value reported by LDSC less than the Bonferroni threshold, here defined as 0.05/6 tests = 8 × 10^{-3}. Only ADHD and OCD have genetic correlations with TS that pass this threshold. These disorders have been noted as among the highest comorbid diagnoses in TS cases.

have genome-wide significance for linkage. Thus, all of these genes require additional independent evidence before being classified as TS risk genes.

De novo *coding SNVs and indels*

Three studies so far have applied WES to investigate rare *de novo* variants in large TS simplex cohorts. Willsey et al. called *de novo* coding variants across 511 TS trios and using a Transmission and *De novo* Association (TADA) framework, identified WW and C2 domain containing 1 (*WWC1*), cadherin EGF LAG seven-pass G-type receptor 3 (*CELSR3*), NIPBL cohesin loading factor (*NIPBL*), and fibronectin 1 (*FN1*) as probable risk genes for TS (Willsey et al., 2017). The sequencing of 291 additional TS trios led to a follow-up analysis on a total of 802 trios by Wang and colleagues, who identified *CELSR3* as a high-confidence TS risk gene and observed an enrichment of *de novo* damaging variants in genes involved in cell polarity (Wang et al., 2018). The study also found a statistically significant excess of damaging *de novo* variants in mutation-intolerant genes in simplex families but not in multiplex families. Across included trios, around 10% of clinical cases carried *de novo* damaging coding variants that likely mediate TS risk, and authors estimated that around 483 genes total may contribute to TS risk when impacted by these variants. Additionally, they noted an overlap of *de novo* sequence variants between TS and OCD, consistent with shared genetic risk. Liu et al. (2020) analyzed WES data from 97 TS trios and identified a *de novo* missense variant in the neurodevelopmental risk gene *ASH1L* alongside some evidence of missense variant overtransmission from parents to probands in the cohort (Coe et al., 2019; Satterstrom et al., 2020). Finally, *de novo* variants from a much smaller cohort of 15 trios were described in a fourth smaller study from Zhao et al. (2020), including a missense variant in the neurodevelopmental gene *KMT2C* (Coe et al., 2019; Satterstrom et al., 2020).

Potential for whole genome sequencing studies of TS

Whole genome sequencing (WGS) could be applied to TS cases to fully characterize genetic contributions to overall risk. WGS allows for the complete characterization of common and rare variation present in each patient. These include all variants detectable in array and WES data, along with rare noncoding SNVs and indels that are outside the reach of these other assays. WGS can also be used to detect CNV deletions and duplications that are too small to be reliably detected in array data, along with inversions and translocations that are undetectable via array or WES (Mills et al., 2011). Analyses of WGS data have proven difficult, in part because deleterious noncoding variants are still not well-defined (Halvorsen et al., 2020). In addition, the computational burden of storage and analysis is higher for WGS than for array or WES. With costs of WGS decreasing over time, it is too early to make a final judgment on whether or not WGS yields good returns on investment for the study of psychiatric disease.

Study of postmortem TS brain tissue

Existing studies focused on postmortem TS brain tissue are small in number and in sample size. Neuroimaging studies have consistently reported abnormalities of the CSTC circuit function in TS pathophysiology (Albin & Mink, 2006; Felling & Singer, 2011). TS patients have been observed to have lower volumes of basal ganglia, a brain region which is connected to the CSTC and exerts control over motor function (Felling & Singer, 2011; Peterson et al., 2003). Two studies focused on postmortem brain tissue from a single set of five TS cases have investigated alterations in neuronal cell populations. Both studies report a decrease in GABAergic and cholinergic interneurons in the striatum, a component of the basal ganglia (Kalanithi et al., 2005; Kataoka et al., 2010). Aligning with this, a transcriptome study of postmortem brain tissue from nine TS cases *v.* nine matched controls describes

lower case expression of transcripts preferentially expressed in striatal interneurons (Lennington et al., 2016).

Discussion

Current literature support a significant role for genetics in TS etiology. The concordance of TS and more generalized presence of tics in twin studies are consistent with a genetic contribution to risk. Studies of medical registry data report that having relatives with TS/CTD is a significant risk factor for TS/CTD diagnosis. Along the same lines, twin studies indicate that the heritability of tic disorders is higher when a broad phenotype is used, rather than TS strictly defined (Price et al., 1985). These findings imply that at the genetic level, TS/CTD fall along a continuum and not into the distinct categories implied by the current diagnostic criteria (Insel et al., 2010). Although early studies of individual large pedigrees did not yield strongly-evidenced findings that were easily-replicated, subsequent studies across thousands of cases have found evidence for a genetic architecture that is specific to TS risk.

Current GWAS focused on TS support a significant contribution from common genetic variation to overall TS risk. Two TS-focused GWAS have been published, each with no genome-wide significant hits that have survived replication analyses. In the most recent analysis, a significant overall SNP-based heritability was noted across the cohort, with a higher heritability estimate obtained from the subset of the cohort that came from multiplex family structures. Individual-level GRS values calculated across samples in these data were associated with both TS and the presence of tics, along with lifetime worst-ever tic severity scores (Yu et al., 2019). These findings are consistent with TS genetic risk from common variation acting in a dosage dependent manner, with higher dosing of the risk alleles leading to greater tic severity and a higher likelihood of TS diagnosis.

Studies of rare variation have proven effective at identifying specific risk genes for TS. So far, two genic rare CNVs (deletions overlapping *NRXN1* and duplications overlapping *CNTN6*) have been identified as significant genetic risk factors for TS risk (Huang et al., 2017). In addition, Wang and colleagues report that *de novo* genic CNVs are associated with TS, particularly within simplex families (without a family history of a tic disorder) (Wang et al., 2018). In studies of *de novo* coding SNVs and indels, a total of six genes that are at least classifiable as probable risk genes have been identified thus far, including *CELSR3* which is classifiable as a high confidence TS risk gene (Wang et al., 2018). Such genes likely represent core risk genes whose perturbation is directly related to TS etiology. As with other similar studies on different psychiatric disorders, future studies will need larger sample sizes in order to identify additional core risk genes for TS (Iakoucheva, Muotri, & Sebat, 2019).

For the risk genes identified so far ($n = 8$ with status of at least 'probable' or declared as genome-wide significant) it is likely that the function of all is directly relevant to TS neurobiology and pathogenesis. Wang et al. noted that two of their six identified genes (*CELSR3* and *WWC1*) have roles in establishing cell polarity, and found that genes with this precise role were enriched in damaging mutations (Wang et al., 2018). Ultimately, it is likely that when perturbed, TS risk genes contribute to the development of the disorder through a variety of effects on neurodevelopment and brain functionality, and that the disruption of this process is simply one of many involved in TS etiology.

Significant progress has been made in deducing and quantifying the genetic contribution of common and rare variation to TS risk. Through collaborative study in consortia that include the Tourette Syndrome Association International Consortium for Genetics (TSAICG) and Tourette International Collaborative (TIC) Genetics in the United States, and the European Multicentre Tics in Children Studies (EMTics) in the European Union, researchers are actively working to identify additional common and rare risk variation, and the TS risk genes that are impacted by them.

References

125 Years of Tourette Syndrome: The Discovery, Early History and Future of the Disorder. (n.d.). *Quarterly Newsletter of the Tourette Association*, 38(3). Retrieved from https://tourette.org/resource/125-years-tourette-syndrome-discovery-early-history-future-disorder/

Albin, R. L., & Mink, J. W. (2006). Recent advances in Tourette syndrome research. *Trends in Neurosciences*, 29(3), 175–182. https://doi.org/10.1016/j.tins.2006.01.001

American Psychiatric Association. (1952). *Diagnostic and statistical manual of mental disorders* (1st ed.). Washington, DC: American Psychiatric Association.

American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Arlington, VA: American Psychiatric Association. https://doi.org/10.1176/appi.books.9780890425596.

1000 Genomes Project Consortium, Auton, A., Brooks, L. D., Durbin, R. M., Garrison, E. P., Kang, H. M., … Abecasis, G. R. (2015). A global reference for human genetic variation. *Nature*, 526(7571), 68–74. https://doi.org/10.1038/nature15393

Browne, H. A., Hansen, S. N., Buxbaum, J. D., Gair, S. L., Nissen, J. B., Nikolajsen, K. H., … Grice, D. E. (2015). Familial clustering of tic disorders and obsessive-compulsive disorder. *JAMA Psychiatry*, 72(4), 359–366. https://doi.org/10.1001/jamapsychiatry.2014.2656

Bulik-Sullivan, B. K., Loh, P.-R., Finucane, H. K., Ripke, S., Yang, J., Schizophrenia Working Group of the Psychiatric Genomics Consortium, … Neale, B. M. (2015). LD score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nature Genetics*, 47(3), 291–295. https://doi.org/10.1038/ng.3211

Coe, B. P., Stessman, H. A. F., Sulovari, A., Geisheker, M. R., Bakken, T. E., Lake, A. M., … Eichler, E. E. (2019). Neurodevelopmental disease genes implicated by de novo mutation and copy number variation morbidity. *Nature Genetics*, 51(1), 106–116. https://doi.org/10.1038/s41588-018-0288-4

Crittenden, J. R., & Graybiel, A. M. (2011). Basal ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. *Frontiers in Neuroanatomy*, 5, 59. https://doi.org/10.3389/fnana.2011.00059

Curtis, D., Robertson, M. M., & Gurling, H. M. (1992). Autosomal dominant gene transmission in a large kindred with Gilles de la Tourette syndrome. *The British Journal of Psychiatry: The Journal of Mental Science*, 160, 845–849. https://doi.org/10.1192/bjp.160.6.845

de Jong, S., Diniz, M. J. A., Saloma, A., Gadelha, A., Santoro, M. L., Ota, V. K., … Breen, G. (2018). Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder. *Communications Biology*, 1, 163. https://doi.org/10.1038/s42003-018-0155-y

Demontis, D., Walters, R. K., Martin, J., Mattheisen, M., Als, T. D., Agerbo, E., … Neale, B. M. (2019). Discovery of the first genome-wide significant risk

loci for attention deficit/hyperactivity disorder. *Nature Genetics*, 51(1), 63–75. https://doi.org/10.1038/s41588-018-0269-7

Duncan, L., Yilmaz, Z., Gaspar, H., Walters, R., Goldstein, J., Anttila, V., … Bulik, C. M. (2017). Significant locus and metabolic genetic correlations revealed in genome-wide association study of anorexia nervosa. *The American Journal of Psychiatry*, 174(9), 850–858. https://doi.org/10.1176/appi.ajp.2017.16121402

Eapen, V., Pauls, D. L., & Robertson, M. M. (1993). Evidence for autosomal dominant transmission in Tourette's syndrome. United Kingdom cohort study. *The British Journal of Psychiatry: The Journal of Mental Science*, 162, 593–596. https://doi.org/10.1192/bjp.162.5.593

Elstner, K., Selai, C. E., Trimble, M. R., & Robertson, M. M. (2001). Quality of life (QOL) of patients with Gilles de la Tourette's syndrome. *Acta Psychiatrica Scandinavica*, 103(1), 52–59. https://doi.org/10.1034/j.1600-0447.2001.00147.x

Ercan-Sencicek, A. G., Stillman, A. A., Ghosh, A. K., Bilguvar, K., O'Roak, B. J., Mason, C. E., … State, M. W. (2010). L-Histidine decarboxylase and Tourette's syndrome. *The New England Journal of Medicine*, 362(20), 1901–1908. https://doi.org/10.1056/NEJMoa0907006

Felling, R. J., & Singer, H. S. (2011). Neurobiology of Tourette syndrome: Current status and need for further investigation. *The Journal of Neuroscience*, 31(35), 12387–12395. https://doi.org/10.1523/JNEUROSCI.0150-11.2011

Ferenczi, S.. (1921). Psycho-analytical observations on tic. *International Journal of Psycho-Analysis*, 2, 1–30.

Fernandez, T. V., Sanders, S. J., Yurkiewicz, I. R., Ercan-Sencicek, A. G., Kim, Y.-S., Fishman, D. O., … State, M. W. (2012). Rare copy number variants in Tourette syndrome disrupt genes in histaminergic pathways and overlap with autism. *Biological Psychiatry*, 71(5), 392–402. https://doi.org/10.1016/j.biopsych.2011.09.034

Fernández de la Cruz, L., Rydell, M., Runeson, B., Brander, G., Rück, C., D'Onofrio, B. M., … Mataix-Cols, D. (2017). Suicide in Tourette's and chronic tic disorders. *Biological Psychiatry*, 82(2), 111–118. https://doi.org/10.1016/j.biopsych.2016.08.023

Freeman, R. D., Fast, D. K., Burd, L., Kerbeshian, J., Robertson, M. M., & Sandor, P. (2000). An international perspective on Tourette syndrome: Selected findings from 3500 individuals in 22 countries. *Developmental Medicine and Child Neurology*, 42(7), 436–447. https://doi.org/10.1017/s0012162200000839

Groth, C., Mol Debes, N., Rask, C. U., Lange, T., & Skov, L. (2017). Course of Tourette syndrome and comorbidities in a large prospective clinical study. *Journal of the American Academy of Child and Adolescent Psychiatry*, 56(4), 304–312. https://doi.org/10.1016/j.jaac.2017.01.010

Grove, J., Ripke, S., Als, T. D., Mattheisen, M., Walters, R. K., Won, H., … Børglum, A. D. (2019). Identification of common genetic risk variants for autism spectrum disorder. *Nature Genetics*, 51(3), 431–444. https://doi.org/10.1038/s41588-019-0344-8

Guyatt, A. L., Stergiakouli, E., Martin, J., Walters, J., O'Donovan, M., Owen, M., … Gaunt, T. R. (2018). Association of copy number variation across the genome with neuropsychiatric traits in the general population. *American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics*, 177(5), 489–502. https://doi.org/10.1002/ajmg.b.32637

Halvorsen, M., Huh, R., Oskolkov, N., Wen, J., Netotea, S., Giusti-Rodriguez, P., … Szatkiewicz, J. P. (2020). Increased burden of ultra-rare structural variants localizing to boundaries of topologically associated domains in schizophrenia. *Nature Communications*, 11(1), 1842. https://doi.org/10.1038/s41467-020-15707-w

Hirschtritt, M. E., Lee, P. C., Pauls, D. L., Dion, Y., Grados, M. A., Illmann, C., … Tourette Syndrome Association International Consortium for Genetics. (2015). Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. *JAMA Psychiatry*, 72(4), 325–333. https://doi.org/10.1001/jamapsychiatry.2014.2650

Huang, A. Y., Yu, D., Davis, L. K., Sul, J. H., Tsetsos, F., Ramensky, V., … Gilles de la Tourette Syndrome GWAS Replication Initiative (GGRI). (2017). Rare copy number variants in NRXN1 and CNTN6 increase risk for Tourette syndrome. *Neuron*, 94(6), 1101-1111, e7. https://doi.org/10.1016/j.neuron.2017.06.010

Iakoucheva, L. M., Muotri, A. R., & Sebat, J. (2019). Getting to the cores of autism. *Cell*, 178(6), 1287–1298. https://doi.org/10.1016/j.cell.2019.07.037

Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., … Wang, P. (2010). Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. *The American Journal of Psychiatry*, 167(7), 748–751. https://doi.org/10.1176/appi.ajp.2010.09091379

International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD Collaborative Genetics Association Studies (OCGAS). (2018). Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. *Molecular Psychiatry*, 23(5), 1181–1188. https://doi.org/10.1038/mp.2017.154

Kalanithi, P. S. A., Zheng, W., Kataoka, Y., DiFiglia, M., Grantz, H., Saper, C. B., … Vaccarino, F. M. (2005). Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome. *Proceedings of the National Academy of Sciences of the United States of America*, 102 (37), 13307–13312. https://doi.org/10.1073/pnas.0502624102

Kataoka, Y., Kalanithi, P. S. A., Grantz, H., Schwartz, M. L., Saper, C., Leckman, J. F., & Vaccarino, F. M. (2010). Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. *The Journal of Comparative Neurology*, 518(3), 277–291. https://doi.org/10.1002/cne.22206

Knight, T., Steeves, T., Day, L., Lowerison, M., Jette, N., & Pringsheim, T. (2012). Prevalence of tic disorders: A systematic review and meta-analysis. *Pediatric Neurology*, 47(2), 77–90. https://doi.org/10.1016/j.pediatrneurol.2012.05.002

Kurlan, R., Behr, J., Medved, L., Shoulson, I., Pauls, D., Kidd, J. R., & Kidd, K. K. (1986). Familial Tourette's syndrome: Report of a large pedigree and potential for linkage analysis. *Neurology*, 36(6), 772–776. https://doi.org/10.1212/wnl.36.6.772

Kushner, H. I. (2000). A brief history of Tourette syndrome. *Revista Brasileira de Psiquiatria*, 22(2), 76–79. https://doi.org/10.1590/S1516-44462000000200008

Leckman, J. F., Bloch, M. H., Scahill, L., & King, R. A. (2006). Tourette syndrome: The self under siege. *Journal of Child Neurology*, 21(8), 642–649. https://doi.org/10.1177/08830738060210081001

Leckman, J. F., Riddle, M. A., Hardin, M. T., Ort, S. I., Swartz, K. L., Stevenson, J., & Cohen, D. J. (1989). The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity. *Journal of the American Academy of Child and Adolescent Psychiatry*, 28(4), 566–573. https://doi.org/10.1097/00004583-198907000-00015

Leckman, J. F., Walker, D. E., & Cohen, D. J. (1993). Premonitory urges in Tourette's syndrome. *The American Journal of Psychiatry*, 150(1), 98–102. https://doi.org/10.1176/ajp.150.1.98

Leckman, J. F., Zhang, H., Vitale, A., Lahnin, F., Lynch, K., Bondi, C., … Peterson, B. S. (1998). Course of tic severity in Tourette syndrome: The first two decades. *Pediatrics*, 102(1 Pt 1), 14–19. https://doi.org/10.1542/peds.102.1.14

Lennington, J. B., Coppola, G., Kataoka-Sasaki, Y., Fernandez, T. V., Palejev, D., Li, Y., … Vaccarino, F. M. (2016). Transcriptome analysis of the human striatum in Tourette syndrome. *Biological Psychiatry*, 79(5), 372–382. https://doi.org/10.1016/j.biopsych.2014.07.018

Levy, R. J., Xu, B., Gogos, J. A., & Karayiorgou, M. (2012). Copy number variation and psychiatric disease risk. *Methods in Molecular Biology* (Clifton, N.J.), 838, 97–113. https://doi.org/10.1007/978-1-61779-507-7_4

Lichtenstein, P., Carlström, E., Råstam, M., Gillberg, C., & Anckarsäter, H. (2010). The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. *The American Journal of Psychiatry*, 167(11), 1357–1363. https://doi.org/10.1176/appi.ajp.2010.10020223

Liu, S., Tian, M., He, F., Li, J., Xie, H., Liu, W., … Guan, J.-S. (2020). Mutations in ASH1L confer susceptibility to Tourette syndrome. *Molecular Psychiatry*, 25(2), 476–490. https://doi.org/10.1038/s41380-019-0560-8

Martin, J., Tammimies, K., Karlsson, R., Lu, Y., Larsson, H., Lichtenstein, P., & Magnusson, P. K. E. (2019). Copy number variation and neuropsychiatric problems in females and males in the general population. *American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics*, 180(6), 341–350. https://doi.org/10.1002/ajmg.b.32685

Mataix-Cols, D., Isomura, K., Pérez-Vigil, A., Chang, Z., Rück, C., Larsson, K. J., … Lichtenstein, P. (2015). Familial risks of Tourette syndrome and chronic Tic disorders. A population-based cohort study. *JAMA Psychiatry*, 72(8), 787–793. https://doi.org/10.1001/jamapsychiatry.2015.0627

McGrath, L. M., Yu, D., Marshall, C., Davis, L. K., Thiruvahindrapuram, B., Li, B., … Scharf, J. M. (2014). Copy number variation in obsessive-compulsive

disorder and Tourette syndrome: A cross-disorder study. *Journal of the American Academy of Child and Adolescent Psychiatry*, *53*(8), 910–919. https://doi.org/10.1016/j.jaac.2014.04.022

McNaught, K. S. P., & Mink, J. W. (2011). Advances in understanding and treatment of Tourette syndrome. *Nature Reviews. Neurology*, *7*(12), 667–676. https://doi.org/10.1038/nrneurol.2011.167

Meier, S. M., Dalsgaard, S., Mortensen, P. B., Leckman, J. F., & Plessen, K. J. (2017). Mortality risk in a nationwide cohort of individuals with tic disorders and with Tourette syndrome. *Movement Disorders*, *32*(4), 605–609. https://doi.org/10.1002/mds.26939

Mills, R. E., Walter, K., Stewart, C., Handsaker, R. E., Chen, K., Alkan, C., … 1000 Genomes Project. (2011). Mapping copy number variation by population-scale genome sequencing. *Nature*, *470*(7332), 59–65. https://doi.org/10.1038/nature09708

Nag, A., Bochukova, E. G., Kremeyer, B., Campbell, D. D., Muller, H., Valencia-Duarte, A. V., … Ruiz-Linares, A. (2013). CNV Analysis in Tourette syndrome implicates large genomic rearrangements in COL8A1 and NRXN1. *PLoS One*, *8*(3), e59061. https://doi.org/10.1371/journal.pone.0059061

O'Rourke, J. A., Scharf, J. M., Yu, D., & Pauls, D. L. (2009). The genetics of Tourette syndrome: A review. *Journal of Psychosomatic Research*, *67*(6), 533–545. https://doi.org/10.1016/j.jpsychores.2009.06.006

Peterson, B. S., Thomas, P., Kane, M. J., Scahill, L., Zhang, H., Bronen, R., … Staib, L. (2003). Basal ganglia volumes in patients with Gilles de la Tourette syndrome. *Archives of General Psychiatry*, *60*(4), 415–424. https://doi.org/10.1001/archpsyc.60.4.415

Polderman, T. J. C., Benyamin, B., de Leeuw, C. A., Sullivan, P. F., van Bochoven, A., Visscher, P. M., & Posthuma, D. (2015). Meta-analysis of the heritability of human traits based on fifty years of twin studies. *Nature Genetics*, *47*(7), 702–709. https://doi.org/10.1038/ng.3285

Price, R. A., Kidd, K. K., Cohen, D. J., Pauls, D. L., & Leckman, J. F. (1985). A twin study of Tourette syndrome. *Archives of General Psychiatry*, *42*(8), 815–820. https://doi.org/10.1001/archpsyc.1985.01790310077011

Qi, Y., Zheng, Y., Li, Z., & Xiong, L. (2017). Progress in genetic studies of Tourette's syndrome. *Brain Sciences*, *7*(10), 134. https://doi.org/10.3390/brainsci7100134.

Redon, R., Ishikawa, S., Fitch, K. R., Feuk, L., Perry, G. H., Andrews, T. D., … Hurles, M. E. (2006). Global variation in copy number in the human genome. *Nature*, *444*(7118), 444–454. https://doi.org/10.1038/nature05329

Robertson, M. M. (2000). Tourette syndrome, associated conditions and the complexities of treatment. *Brain: A Journal of Neurology*, *123*(Pt 3), 425–462. https://doi.org/10.1093/brain/123.3.425

Robertson, M. M. (2008). The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1: The epidemiological and prevalence studies. *Journal of Psychosomatic Research*, *65*(5), 461–472. https://doi.org/10.1016/j.jpsychores.2008.03.006

Robertson, M. M., Eapen, V., Singer, H. S., Martino, D., Scharf, J. M., Paschou, P., … Leckman, J. F. (2017). Gilles de la Tourette syndrome. *Nature Reviews. Disease Primers*, *3*, 16097. https://doi.org/10.1038/nrdp.2016.97

Sanders, S. J., He, X., Willsey, A. J., Ercan-Sencicek, A. G., Samocha, K. E., Cicek, A. E., … State, M. W. (2015). Insights into autism spectrum disorder genomic architecture and biology from 71 risk loci. *Neuron*, *87*(6), 1215–1233. https://doi.org/10.1016/j.neuron.2015.09.016

Satterstrom, F. K., Kosmicki, J. A., Wang, J., Breen, M. S., De Rubeis, S., An, J.-Y., … Buxbaum, J. D. (2020). Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. *Cell*, *180*(3), 568–584, e23. https://doi.org/10.1016/j.cell.2019.12.036

Scharf, J. M., Miller, L. L., Gauvin, C. A., Alabiso, J., Mathews, C. A., & Ben-Shlomo, Y. (2015). Population prevalence of Tourette syndrome: A systematic review and meta-analysis. *Movement Disorders*, *30*(2), 221–228. https://doi.org/10.1002/mds.26089

Scharf, J. M., Yu, D., Mathews, C. A., Neale, B. M., Stewart, S. E., Fagerness, J. A., … Pauls, D. L. (2013). Genome-wide association study of Tourette's syndrome. *Molecular Psychiatry*, *18*(6), 721–728. https://doi.org/10.1038/mp.2012.69

Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014). Biological insights from 108 schizophrenia-associated genetic loci. *Nature*, *511*(7510), 421–427. https://doi.org/10.1038/nature13595

Shapiro, A. K., & Shapiro, E. (1968). Treatment of Gilles de la Tourette's syndrome with haloperidol. *The British Journal of Psychiatry: The Journal of Mental Science*, *114*(508), 345–350. https://doi.org/10.1192/bjp.114.508.345

Singer, H. S. (2013). Motor control, habits, complex motor stereotypies, and Tourette syndrome. *Annals of the New York Academy of Sciences*, *1304*, 22–31. https://doi.org/10.1111/nyas.12281

Stafford, M., & Cavanna, A. E. (2020). Prevalence and clinical correlates of self-injurious behavior in Tourette syndrome. *Neuroscience and Biobehavioral Reviews*, *113*, 299–307. https://doi.org/10.1016/j.neubiorev.2020.03.022

Stahl, E. A., Breen, G., Forstner, A. J., McQuillin, A., Ripke, S., Trubetskoy, V., … Bipolar Disorder Working Group of the Psychiatric Genomics Consortium. (2019). Genome-wide association study identifies 30 loci associated with bipolar disorder. *Nature Genetics*, *51*(5), 793–803. https://doi.org/10.1038/s41588-019-0397-8

Sudmant, P. H., Rausch, T., Gardner, E. J., Handsaker, R. E., Abyzov, A., Huddleston, J., … Korbel, J. O. (2015). An integrated map of structural variation in 2504 human genomes. *Nature*, *526*(7571), 75–81. https://doi.org/10.1038/nature15394

Sun, N., Nasello, C., Deng, L., Wang, N., Zhang, Y., Xu, Z., … Tischfield, J. A. (2018). The PNKD gene is associated with Tourette disorder or tic disorder in a multiplex family. *Molecular Psychiatry*, *23*(6), 1487–1495. https://doi.org/10.1038/mp.2017.179

Sundaram, S. K., Huq, A. M., Sun, Z., Yu, W., Bennett, L., Wilson, B. J., … Chugani, H. T. (2011). Exome sequencing of a pedigree with Tourette syndrome or chronic tic disorder. *Annals of Neurology*, *69*(5), 901–904. https://doi.org/10.1002/ana.22398

Sundaram, S. K., Huq, A. M., Wilson, B. J., & Chugani, H. T. (2010). Tourette syndrome is associated with recurrent exonic copy number variants. *Neurology*, *74*(20), 1583–1590. https://doi.org/10.1212/WNL.0b013e3181e0f147

Szatkiewicz, J., Crowley, J. J., Adolfsson, A. N., Åberg, K. A., Alaerts, M., Genovese, G., … Sullivan, P. F. (2019). The genomics of major psychiatric disorders in a large pedigree from Northern Sweden. *Translational Psychiatry*, *9*(1), 60. https://doi.org/10.1038/s41398-019-0414-9

Tourette, G. (1885). *Étude sur une affection nerveuse caractérisée par de l'incoordination motrice accompagnée d'écholalie et de coprolalie*. 1885 (19–42).

Wang, S., Mandell, J. D., Kumar, Y., Sun, N., Morris, M. T., Arbelaez, J., … State, M. W. (2018). De novo sequence and copy number variants Are strongly associated with Tourette disorder and implicate cell polarity in pathogenesis. *Cell Reports*, *24*(13), 3441–3454, e12. https://doi.org/10.1016/j.celrep.2018.08.082…

Willsey, A. J., Fernandez, T. V., Yu, D., King, R. A., Dietrich, A., Xing, J., … Heiman, G. A. (2017). De novo coding variants Are strongly associated with Tourette disorder. *Neuron*, *94*(3), 486–499, e9. https://doi.org/10.1016/j.neuron.2017.04.024

Yilmaz, Z., Halvorsen, M., Bryois, J., Yu, D., Thornton, L. M., & Zerwas, S., … Eating Disorders Working Group of the Psychiatric Genomics Consortium, T. S. D. W. G. of the P. G. C. (2018). Examination of the shared genetic basis of anorexia nervosa and obsessive-compulsive disorder. *Molecular Psychiatry*, *53*(8), 910–919. https://doi.org/10.1038/s41380-018-0115-4.

Yu, D., Sul, J. H., Tsetsos, F., Nawaz, M. S., Huang, A. Y., Zelaya, I., … Tourette Association of America International Consortium for Genetics, the Gilles de la Tourette GWAS Replication Initiative, the Tourette International Collaborative Genetics Study, and the Psychiatric Genomics Consortium Tourette Syndrome Working Group. (2019). Interrogating the genetic determinants of Tourette's syndrome and other tic disorders through genome-wide association studies. *The American Journal of Psychiatry*, *176*(3), 217–227. https://doi.org/10.1176/appi.ajp.2018.18070857

Zhao, X., Wang, S., Hao, J., Zhu, P., Zhang, X., & Wu, M. (2020). A whole-exome sequencing study of Tourette disorder in a Chinese population. *DNA and Cell Biology*, *39*(1), 63–68. https://doi.org/10.1089/dna.2019.4746